Mr. Amardeep Sethi, C.E.O., Kirloskar Technologies addressing the gathering of more than 50 interventional cardiologists from all over India at the ACVS – India (Advanced Cardiovascular Solutions) organized at Hyderabad from 19th to 21st Aug, 2011.

Download Full Article

Introducing a new phase in Interventional Cardiology

New Delhi: November 12, 2010: Interventional Cardiology will witness a new phase with the launch of MGuard™, India’s first mesh based coronary stent, by Kirloskar Technologies Pvt. Ltd. (KTPL). The newly introduced MGuard™ Coronary Stent System is manufactured by InspireMD, Ltd. an innovative medical device company focused on the development and deployment of its proprietary stent system technology.

The launch of MGuard™ is followed by a Live Surgery at the Medicity Hospital, Gurgaon. Commenting during the launch of MGuard™ in India Prof. Yaron Almagor, visiting Surgeon & Director, Cardiac Catheterization and Interventional Cardiology Laboratories, Jesselson Heart Center, Shaare Zedek Medical Center, Jerusalem said "Despite the constant improvement we have seen in recent years in the treatment of heart attack patients, distal embolization is still a problem that affects a significant portion of patients who are treated with primary PCI and it's a major cause for morbidity and mortality. Based on my experience, the MGuard stent improves the procedure safety, reduces complications and leads to a better outcome in this high risk population.”

Dr. Praveen Chandra, the leading Interventional Cardiologist and Chairman, Division of Interventional Cardiology Department at Medicity Hospital said “I am happy that for the first time the patients in India will have this unique Stent – Mguard. It will go a long way in attending to the uncatered patients group.”

The MGuard™ Coronary Stent System presents a novel combination of a coronary stent merged with an embolic protection device. The embolic protection device is comprised of an ultra-thin polymer mesh protective sleeve, wrapped around the stent. The protective sleeve is designed to expand seamlessly when the stent is deployed, without affecting the structural integrity of the stent, and to prevent plaque detachment during and post procedure. The MGuard™ Coronary Stent System provides long acting embolic protection, without adding complexity to the deliverability. The sleeve is designed to diffuse stent pressure on the vessel wall, thereby reduce injury and lower the likelihood of restenosis.

Mr. Amardeep Sethi, CEO Kirloskar Technologies Pvt Ltd., also present for the launch said, “The unique MGuard™ System includes an exclusive protective net that minimizes the escaping of emboli into the bloodstream during and post procedure and reduces damage to the arterial wall, - this in other way lessens the chance of Myocardial Infarction”. Mr. Sethi further added that cardiac problem is one of the major lifestyle diseases that India is facing these days. Based on statistical data, the number one killer among all diseases in the world right now is Heart Disease. Hence advanced state-of-the-art solution is a need of the hour.

Adding further, Mr. Ofir Paz, InspireMD’s CEO said, “The MGuard™ Coronary Stent System innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world. Today, more and more medical practitioners are realizing the importance improving the outcome of Acute MI patients. This breakthrough system has already been a huge success in Israel and European countries and hence we are confident that in India as well it would be greatly appreciated and accepted”

The MGuard™ Coronary Stent System will be available in Delhi, Mumbai, Trivandrum, Kolkata, Chandigarh, Lucknow, Hyderabad, Bangalore, Chennai, Pune & North East.

About KTPL:

Kirloskar Technologies is one of the leading suppliers of high-tech medical equipment in India and is part of the 100 year old multi –billion dollar Kirloskar Group. Kirloskar KTPL has a widespread presence in hospitals in India with products for oncology, neurology, gynecology and cardiology.

About InspireMD

InspireMD, Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. MGuard™ is CE Mark approved and currently sold in over 40 countries worldwide.

For further media queries please contact:

Arpita Sinha
Lexicon Public Relations
Tel. No. Mob. + 98716 06139
Landline: 011-26234726, 26223099

On behalf of the Kirloskar Group, Mr. Atul Kirloskar recieved the prestigious Maharashtra Ratna Award, given to eminent personalities, at the hands of Smt. Pratibha Devisingh Patil, Hon'ble President of India on 51st Maharashtra Day Celebration.

• Sales Executives - No. of positions: 15 in various towns
  Science/pharmacy graduates with 3-4 years field experience of selling interventional cardiology/cath. lab. products or related drugs. MBAs in marketing will be preferred.
• Regional Sales Managers - for East and North/ West and South
  Team leaders with sciences/pharmacy graduation/MBA having 7-8 years hard core experience in selling interventional cardiology products. Good contacts with major Cath. labs. is necessary.
• All India Sales Manager
  Result oriented, dynamic sales professional who can lead inspired team from the front. An MBA with science/pharmacy degree having 10-12 years experience in marketing interventional cardiology/cath. lab. products or related drugs, with an in-depth understanding of the market at All-India level will get preference.

Salary and perks will be commensurate with qualifications and experience. Post your resume along with a full length photograph to: hr@kirloskarmedical.com within ten days.

Mr. Amardeep Sethi, CEO launches ExAblate 2000.

ExAblate Launch - Hyderabad

ExAblate Launch - Bangalore

Kirloskar Technologies Launches

Mumbai Jan 15, 2010: With the launch of ExAblate 2000 in India by Kirloskar Technologies, a leading provider of high technology life saving devices, the treatment of Uterine Fibroids amongst Indian women receives a huge boost.  The Non Invasive Magnetic Resonance guided Ultrasound surgery machine (MRgFUS) reduces chances of infertility and offers significant advantages over the existing treatments.  The new Technology will help women reduce the risk of removal of uterus, which is very high in case of surgeries.

With the first ExAblate 2000 installed at Jaslok Mumbai, it would be the first hospital in India to offer this treatment to patients. This major technology development in the healthcare industry is expected to be a boon to the medical fraternity  and specially to the women who currently undergo a rigorous procedure in the treatment for uterine fibroids. Study says that 20 to 40% of women age 35 and older have uterine fibroid of a significant size with Indian women being  at a far higher risk for fibroids  with as many as 50 % having  fibroids of various sizes. 

Discussing during the launch of this new equipment in India Dr W.M Gedroyc, Medical Director, MRU, St Mary’s Hospital, London said “ It is important to properly identify and successfully treat patients with uterine fibroids and one of the primary objectives of KTPL & Insightec is to create awareness about this disease not only amidst the patients/end beneficiaries but also within the medical practitioners “ One of the prominent highlights of this treatment system is that it does not require any anesthesia or hospitalization for the patient. Hence women suffering from this disease do not have to undergo the painful trauma of surgery. 

Commenting on the uniqueness of ExAblate 2000 Mr. Amardeep Sethi, CEO Kirloskar Technologies said, “Uterine fibroids result in more in-patient hospital days than AIDS, breast cancer, dementia, etc. It is estimated that women lose 5-10 million work days annually because of this. In addition to this the recovery stage of a woman post-surgery is the most crucial. In such circumstances the use of ExAblate 2000 turns out to be a much easier and comfortable method compared with current invasive treatment options“.

ExAblate 2000 is a way forward to a new phase of Fibroid surgery in India.  The U.S Food and Drug Administration (FDA) approve this equipment in Oct 2004.

Some facts on Uterine Fibroids 

• Uterine Fibroids occur in every four to five women 
• Uterine Fibroids also known as uterine leimyomata are the most common non cancerous tumors in women of childbearing age.
• Women who are obese or overweight have a slightly higher risk for developing uterine fibroids than women of normal weight
• Generally occurs in women between 30’s to 40’s 
• In India it is found that this disease is common between the age group of 21-30 – 30% & 30+ is 30% 

Additional applications of ExAblate 2000 under investigation are for Brain tumors, Liver tumors, Breast cancer, Prostate cancer, and Bone metastases.

Speaking on the occasion, Roni Yagel, V.P Insightec Ltd remarked “Insightec is pleased to associate itself with Kirloskar Technologies who are leaders in the marketing of Cancer Therapy machines.  Our breakthrough technology product ExAblate 2000 is sure to create a positive impact on the health and productivity of Indian women.”

Col. M. Masand, CEO Jaslok Hospital said, “ I am happy that we have pioneered the use of ExAblate 2000 in Jaslok Hospital, Mumbai.”

Dr. Srinivas Desai explained,  “ The technology used in ExAblate 2000 replaces scalpels to provide surgical benefits without scars, incisions, hospitalization and long recovery time.  I am sure with the introduction of ExAblate 2000, there will be a lot of value addition in treatment of Fibroids and cancer”

Dr. Rishma Pai, Hon. Consultant Jaslok Hospital, informed, “ Every second Indian women has Uterine fibroid affecting their health and productivity.  In majority cases removal of uterus was the only solution leading to a long post-recovery time. Moreover, in many instances uterus has been required to be used again, so we must respect the importance of uterus and not remove it until essential. ExAblate 2000 offers a trouble free, comfortable and quick non-invasive treatment, which is very encouraging.”

About KTPL

Kirloskar Technologies is one of the leading suppliers of high-tech medical equipments in India. It is part of the 100 year old multi –billion dollar Kirloskar Group. With over 250 installations in 175 major government hospitals, medical colleges and private hospitals, the KTPL is the largest player in the Radio Therapy market. 

About Insightec

InSightec Ltd. developed ExAblate 2000, a product that integrates magnetic resonance imaging with focused ultrasound energy as a treatment modality for patients with serious diseases. The company was founded in 1999 and is headquartered in Tirat Carmel, Israel with an additional office in Dallas, Texas.

Geetanjali Kirloskar 

The recession has, thank God, stopped all of us crowing about how India is rising and shining. Giving us time to reflect on it in terms of our personal value systems and not “irrational exuberance”. But did the ‘boom’ pull everybody’s quality of life up? Without doubt, agriculture – only 20 per cent of our GDP but supporting 60 per cent of our population – grew at a healthy clip. The NREGS benefited 44 million families. The debt write-off made the lives of 43 million farmers a little easier. But travelling extensively around India, one cannot say that life for the poor and even lower middle classes has changed substantially over the past decade. 

The tide is coming in and, if we grab the opportunity, every single one of us 1.1 billion Indians can rise. If this tide is not harnessed, it will result in social and economic conflicts leaving India worse off than before. The India growth story is on razor’s edge in almost all dimensions. 

India’s young have driven the growth story. Our educated, English-speaking youth have made India the world’s back office. But the back office business can absorb only a fraction of our almost limitless supply of the young which will continue to increase well into this century’s third decade. India must ensure all its young have a shot at getting educated well. The Right to Education Bill has been passed and i will be rooting for it to achieve its objectives. To paraphrase Franklin Roosevelt, we cannot always build the future for our youth, but we can build our youth for the future. 

India must ensure its educated young have more avenues of productive growth than just the IT-BPO industries. More sectors need to take off. The central challenge is in promoting originality and innovation. India cannot emulate its way to success. We cannot do a US or a Japan. The US’s population density is 30 times lower than India’s. The US had to do a lot less with a lot more resources. But India has time on its side. We can find sustainable growth models that harness modern technology provided we learn from others’ mistakes and innovate. 

India has no dearth of grassroots innovation yielding world class results in diverse fields. Consider the story of Ram Charan. He grew up in a small town in UP. In his early years he worked in his family’s modest shoe shop. As he saw his father juggle the shop’s finances to meet the income rhythms of mostly rural customers, he learnt the importance of carefully managed cash flow. Today he is a world-renowned consultant to global companies. In the recession his practice, unlike that of some consulting giants, is unaffected as he helps clients through turbulent times, adapting the lessons he learnt in his father’s little shop. 

Consider India’s private health care sector. Doctors have fearlessly rejected new technologies like surgical robots and keyhole surgery kits – despite these being popular in the West – as fanciful and not cost-effective. Instead they innovate, making breakthroughs like ‘beating heart’ surgery which causes less pain, does not require general anesthesia, has the patient faster on his feet and costs less! ‘Beating heart’ surgery has medical tourists from across the world flocking to Bangalore. Paul Yock, head of Stanford University’s biodesign laboratory which develops medical devices, thinks that amid growing concerns about runaway health spending, the global industry can find inspiration in India on how to serve need without being blind to cost. 

The Indian as an individual has in every field across the world, including business, demonstrated innovation and originality. But as a society and as communities, India is among the world’s least innovative. In every social sector – public education, public health, public infrastructure, public morality – India is abysmally below world class standards, ranking below 100 in the comity of nations. 

India has always been a land of contrasts. But this contrast between the achievement of individuals and businesses and the continuing rot of India as a society can destroy us all. India must and will find a solution. Indian society needs a new kind of leadership. While the most visible component of a society’s leadership is the people in the corridors of power, an equally if not more important component is at the grassroots: the village sarpanch, the wise teacher whose counsel many seek, the respected NGO worker, the journalist respected for his perspective and his integrity, the spiritual or religious leader who is his community’s rallying point. 

This ecosystem of leadership needs to shift from perpetuating the status quo to being a catalyst of change. To me, the greatest sign of hope is that this is beginning to happen. The general election results were a symptom of this tectonic shift. More important, the most potent political force to emerge from the election is a quiet young man who continues to concentrate on building a new apparatus of leadership at the grassroots. With creative leadership, India will become innovative at the societal level. Combine this with the innovative abilities of individuals and business – and India could reach a strategic inflection point that finally puts it on a path that lifts millions to a life without lack.

The Times of India, August 22, 2009

KTPL team met at its annual get together in April at Heritage Resort, Manesar, Haryana.  Mrs Geetanjali Kirloskar, Chairperson of KTPL, inaugurated the meet. She said “Our large installation base, delivering about 4.5 million treatments annually, puts greater responsibility on our shoulders. We must continue maintaining the high uptime on our machines and achieve excellence in providing quality service.” 

Mr. Vikram Kirloskar, Chairman, Kirloskar Systems Ltd, while declaring the Champions Award function open, complimented the team and remarked, “I have met many customers who have enjoyed your services, friendliness, trust and partnership and when they give you compliments, it makes me feel proud.”

Mr. Amardeep Sethi  spoke about the importance of the role of Corporate Social Responsibility at the recently concluded global seminar of Public Relations professionals at Bangaluru. He dwelt on the role being played by KTPL in fulfilling its social responsibility. 

Over the years KTPL has evolved a technique to build optimum efficiency of the installed machines, so that these run round the clock and provide treatment to more and more patients. This has greatly helped our country, where the gap between the requirement and availability of radiation therapy units is huge. At many hospitals more than 100 patients per day are treated, owing to the reliability of the machines installed by KTPL.

In a significant strategic move to consolidate its position as medical equipment provider outside Oncology market, Kirloskar Technologies (P) Ltd. (KTPL) has inked an agreement with Neusoft Medical Systems, Shenyang, China. This will allow KTPL to market and provide after-sales service to Neusoft diagnostic medical equipments and other products in India.

 Neusoft Medical Systems produces range of diagnostic imaging products such as CT, MRI, X-ray, Ultrasound, and Laser Imager; besides Patient Monitoring Systems and software solution based products like PACS/RIS. 

In June 2004, Neusoft Medical Systems took a strategic move to form a joint venture with Philips. This JV focuses on research and development and manufacturing of CT, MRI, X-Ray and Ultrasound products for the global market.

Neusoft Medical Systems has installations world over, including USA, Europe, South America, Africa, Middle East and Asia for its FDA and CE approved products.

Speaking on the occasion, Mr. Amardeep Sethi, Chief Executive Officer, KTPL said, “Teaming up with Neusoft Medical Systems which is also the largest software solutions provider in China, would be a complete strategic fit with our Oncology business and will also open new markets in the Imaging sector.” He added, “It is very much in keeping with our consistent endeavour to promote  appropriate technologies for the Indian market.”

KTPL are training their competent service engineers to effectively service Neusoft products. KTPL assure customers of the same high standards of support, which they have cherished for long with them, told Jacob Thirumalai, Director, Services.

Mr. Animesh, Vice President Business Development stated, “ KTPL's strong presence, marketing prowess and long standing customer relationship, when married to Neusoft product offerings, shall surely expand radiology market and reach its vastly uncatered segment.”  “We see this alliance meeting long-term latent demand of Indian radiology market," he said.

Mr. Dan Zhang Vice President International Marketing & Sales, Neusoft and Amardeep Sethi, CEO, KTPL sign the agreement. Also seen are Cowley Sun, Director Sales Asia Pacific, Sophie Liu, Marketing Manager and Animesh VP, Business Developement, KTPL.

Dr. K.R. Singh was remembered at the recently concluded PRCI Global Meet at Bangalore. The Organisation has also instituted K.R. Singh Memorial Life Award which will be conferred annually to an accomplished person in India for outstanding life time achievement